KLOW Blend is GLOW Blend plus KPV. Both are single-vial co-formulations built on the same three-peptide core — GHK-Cu, BPC-157 and TB-500 — with GLOW supplying 70 mg total and KLOW adding a fourth component, the anti-inflammatory tripeptide KPV, for 80 mg total. In a KLOW Blend vs GLOW Blend comparison, the only compositional variable is that fourth peptide, which means the choice comes down to one question: does your study design need an inflammatory-signalling arm inside the same vial, or does adding one make the result harder to interpret?
We supply KLOW Blend as an 80 mg lyophilized vial and GLOW Blend as a 70 mg lyophilized vial, both assayed by HPLC per component with a lot-matched certificate, both listed under recovery blends. Both are research chemicals for in-vitro and preclinical laboratory work only, not for human or veterinary use.
KLOW vs GLOW at a glance
| Attribute | KLOW Blend | GLOW Blend |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500, KPV | GHK-Cu, BPC-157, TB-500 |
| Typical split per vial | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg | GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg |
| Total peptide | 80 mg | 70 mg |
| Difference | Adds a 10 mg anti-inflammatory tripeptide arm | Matrix and repair core only |
| GHK-Cu share by mass | 62.5% | 71.4% |
| GHK-Cu share by moles | Approximately 72% | Approximately 87% |
| Reconstituted appearance | Pale blue from the copper complex | Pale blue from the copper complex |
| Research emphasis | Repair plus inflammatory signalling; gut and mucosal designs | Matrix, dermal and connective-tissue designs |
| Preparation steps replaced | Four separate reconstitutions | Three separate reconstitutions |
| Attribution of effects | Not possible from the blend alone | Not possible from the blend alone |
| Format | Lyophilized powder, sealed glass vial | Lyophilized powder, sealed glass vial |
| Purity | ≥99% HPLC per component, lot-matched COA | ≥99% HPLC per component, lot-matched COA |
The shared core, component by component
GHK-Cu is the dominant component in both blends by a wide margin. It is a glycyl-L-histidyl-L-lysine tripeptide complexed with copper(II), first identified in human plasma in the 1970s and studied since in fibroblast culture and skin models, with extracellular matrix turnover, collagen expression and dermal repair as the recurring endpoints. At 403.93 g/mol it is also the lightest component, which magnifies its dominance in molar terms.
BPC-157 is a 15-residue fragment of a cytoprotective protein characterised in human gastric juice, studied mainly in rodent repair models with angiogenic and growth-factor signalling as the proposed mechanism. TB-500 is the acetylated 17–23 fragment of thymosin beta-4, carrying the actin-binding motif associated with cytoskeletal remodelling and cell migration.
KPV — present only in KLOW — is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory signalling including NF-kappaB modulation and epithelial barrier readouts, with no melanocortin receptor activity of its own. Our BPC-157 vs KPV comparison covers how that mechanism differs from the repair components.
Composition arithmetic worth doing before you order
Both blends are numerically dominated by the copper peptide, and by more than the mass split suggests. Converting each component to moles using its molecular weight makes the imbalance explicit.
In GLOW, 50 mg of GHK-Cu at 403.93 g/mol is roughly 124 micromoles, against roughly 7 micromoles of BPC-157 at 1419.55 g/mol and roughly 11 micromoles of TB-500 at 889.02 g/mol — so GHK-Cu accounts for close to 87 percent of the peptide present in molar terms. In KLOW, adding 10 mg of KPV at 342.43 g/mol contributes roughly 29 micromoles, which brings GHK-Cu down to around 72 percent. KPV becomes the second most abundant component by moles despite being tied for the smallest by mass, precisely because it is the lightest molecule in the vial.
The practical consequence is the same for both products: any effect observed with either blend is, on molar grounds, most likely to be a copper-peptide effect with three or four minor contributors alongside it. That is not a criticism of the formulation — it is how the formulations are built — but it is the interpretation a laboratory should start from rather than arrive at.
What a blend can and cannot answer
Co-formulation solves a real problem. Preparing four peptides separately means four reconstitutions, four transfer steps and four opportunities for volumetric error, and the compounding of those errors is a genuine source of irreproducibility in multi-compound designs. A single vial removes all of it, and every component in the vial has been through the same handling history.
What co-formulation cannot do is attribute. If a blend arm produces an effect, the design cannot say whether it came from the copper peptide, from BPC-157, from TB-500, from KPV, or from an interaction. That limitation applies equally to both products and is the single most important thing to understand before choosing either. A study intended to attribute results needs single-component arms alongside the blend arm, prepared from individual vials.
Used correctly, the two blends are actually more informative together than separately. Because KLOW is compositionally identical to GLOW except for KPV, running the two side by side isolates the KPV contribution against a fixed three-peptide background — a subtraction design that neither blend supports on its own. That is the one comparison where the pairing genuinely earns its place in a protocol.
Which to choose for which research question
Choose GLOW for matrix and dermal endpoints
If the readouts are collagen expression, fibroblast behaviour, extracellular matrix turnover or dermal repair, GLOW is the tighter formulation: three components, all with matrix or repair literatures, and no inflammatory-signalling arm to complicate interpretation. It is also the more economical of the two per vial when the fourth component would not be measured anyway.
Choose KLOW when inflammatory signalling is part of the readout
If the model includes an inflammatory component — mucosal or intestinal preparations in particular, where KPV's published record is concentrated — the four-component vial covers that arm without a separate preparation. KLOW is also the appropriate starting point for designs spanning both repair and inflammation endpoints in the same animals.
Choose individual vials when attribution matters
For mechanism work, concentration–response series on any single component, or any result intended to be attributed to a specific molecule, buy the components separately. Neither blend supports that, and no amount of downstream analysis recovers attribution from a co-formulated arm. For a two-component alternative on the repair side, the BPC-157 with TB-500 vial is a simpler formulation with only two contributors; our background piece on how these blends are composed compares the family.
Cost accounting across the two
Comparing blends to their components on a total-milligram basis is straightforward and worth doing. GLOW supplies 70 mg across three peptides in one vial; buying the same three quantities separately — 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 — costs substantially more at list. KLOW adds 10 mg of KPV for a smaller increment than a standalone 10 mg KPV vial. That reflects the economics of a single fill and a single certificate rather than any difference in material.
The counterpoint is that a blend is only economical if you would have used every component. Buying KLOW when the study never measures an inflammatory endpoint means paying for a component that contributes nothing to the result but does contribute to the interpretation problem.
Handling, reconstitution and storage
Both blends follow the same protocol, and the copper complex is what makes it distinctive. Hold sealed vials frozen, bring them to room temperature before piercing the stopper so moisture does not condense on cold powder, run diluent down the vial wall rather than onto the cake, and let the material dissolve without shaking. Reconstituted solution takes on a characteristic pale blue tint from the copper — expected, not a defect. An absence of that tint in a copper-containing blend is a reason to question the vial.
Two copper-specific cautions apply to both. Copper(II) is redox-active, so blends containing it should be kept away from reducing agents and from prolonged light and warmth, and working solutions are best prepared fresh rather than held dilute. Copper also coordinates readily to histidine and to free thiols, so introducing a copper-containing blend into a buffer system with chelators such as EDTA, or with thiol reagents, can alter the complex itself.
Concentration is a laboratory calculation, not a recommendation for use: an 80 mg KLOW vial reconstituted with 4 mL of diluent gives 20 mg/mL of total peptide, of which roughly 12.5 mg/mL is GHK-Cu and 2.5 mg/mL each of the other three. Reporting a blend concentration as total peptide alone is ambiguous — state the per-component concentrations. See our reconstitution guide and storage guide, and aliquot so neither blend is repeatedly frozen and thawed.
Purity, identity and COA checks
A blend certificate should do more than a single-peptide certificate. Ask for per-component purity rather than a single aggregate figure, confirmation of the component ratio in the lot you are buying rather than the nominal split, and a lot number matching the vial. For copper-containing formulations, confirmation of the copper complex rather than free GHK peptide is a meaningful check, since the uncomplexed tripeptide is a different molecule for any copper-dependent interpretation. Our COA guide covers what a complete document should include.
Regulatory framing
KLOW Blend and GLOW Blend are supplied as research chemicals for in-vitro and preclinical laboratory work only. Neither is an approved medicine, a compounded preparation, a supplement or a therapy of any kind, and the published evidence for their components is preclinical. Nothing on this page is a protocol for human or veterinary use. For broader context see our recovery research overview.